{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:28:21Z","timestamp":1786638501121,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,6]]},"DOI":"10.7759\/cureus.66258","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T09:13:30Z","timestamp":1722935610000},"source":"Crossref","is-referenced-by-count":5,"title":["A Systematic Review of the Cardiotoxic Effects of Targeted Therapies in Oncology"],"prefix":"10.7759","author":[{"given":"Wilhelmina N","family":"Hauwanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"McBenedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha K","family":"Dohadwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuwike","family":"Johnny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Asaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyinye D","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmalik","family":"Jimoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada Andrea Oghenerukevwe","family":"Elumah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okam V","family":"Onyinyinyechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulci","family":"Petrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lima Pess\u00f4a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.03.019","article-title":"Mapping cancer origins","volume":"145","author":"Gilbertson RJ","year":"2011","unstructured":"Gilbertson RJ. Mapping cancer origins. Cell. 2011, 145:25-9. 10.1016\/j.cell.2011.03.019","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5935\/2359-4802.20170004","article-title":"Cardiotoxicity of doxorubicin treatment and physical activity: a systematic review","volume":"30","author":"Maia TN","year":"2017","unstructured":"Maia TN, de Araujo GBR, Teixeira JAC, Junior EDA, Dias KP. Cardiotoxicity of doxorubicin treatment and physical activity: a systematic review. Int J Cardiovasc Sci. 2017, 30:70-80. 10.5935\/2359-4802.20170004","journal-title":"Int J Cardiovasc Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024, 74:12-49. 10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010441","article-title":"Cancer therapy-induced cardiotoxicity\u2014a metabolic perspective on pathogenesis, diagnosis and therapy","volume":"23","author":"Choksey A","year":"2021","unstructured":"Choksey A, Timm KN. Cancer therapy-induced cardiotoxicity\u2014a metabolic perspective on pathogenesis, diagnosis and therapy. Int J Mol Sci. 2021, 23:441. 10.3390\/ijms23010441","journal-title":"Int J Mol Sci"},{"key":"ref5","article-title":"Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature","volume":"6","author":"Wojtacki J","year":"2020","unstructured":"Wojtacki J, Lewicka-Nowak E, Le\u015bniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit. 2020, 6:411-20.","journal-title":"Med Sci Monit"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100751","article-title":"A novel scoring system to estimate chemotherapy-induced myocardial toxicity: risk assessment prior to non-anthracycline chemotherapy regimens","volume":"33","author":"\u00d6zt\u00fcrk C","year":"2021","unstructured":"\u00d6zt\u00fcrk C, Validyev D, Becher UM, Weber M, Nickenig G, Tiyerili V. A novel scoring system to estimate chemotherapy-induced myocardial toxicity: risk assessment prior to non-anthracycline chemotherapy regimens. Int J Cardiol Heart Vasc. 2021, 33:100751. 10.1016\/j.ijcha.2021.100751","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2012.11.002","article-title":"Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies","volume":"32","author":"Ad\u00e3o R","year":"2013","unstructured":"Ad\u00e3o R, de Keulenaer G, Leite-Moreira A, Br\u00e1s-Silva C. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies. Rev Port Cardiol. 2013, 32:395-409. 10.1016\/j.repc.2012.11.002","journal-title":"Rev Port Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.035","article-title":"Assessment of prognostic value of high-sensitivity cardiac troponin T for early prediction of chemoradiation therapy-induced cardiotoxicity in patients with non-small cell lung cancer: a secondary analysis of a prospective randomized trial","volume":"111","author":"Xu T","year":"2021","unstructured":"Xu T, Meng QH, Gilchrist SC, et al.. Assessment of prognostic value of high-sensitivity cardiac troponin T for early prediction of chemoradiation therapy-induced cardiotoxicity in patients with non-small cell lung cancer: a secondary analysis of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 2021, 111:907-16. 10.1016\/j.ijrobp.2021.07.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-019-01617-y","article-title":"Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity","volume":"27","author":"Kim J","year":"2020","unstructured":"Kim J, Cho SG, Kang SR, et al.. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2020, 27:2154-63. 10.1007\/s12350-019-01617-y","journal-title":"J Nucl Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei BG","year":"2020","unstructured":"Demissei BG, Hubbard RA, Zhang L, et al.. Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc. 2020, 9:e014708. 10.1161\/JAHA.119.014708","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6039","article-title":"Global longitudinal strain at 3\u2009months after therapy can predict late cardiotoxicity in breast cancer","volume":"12","author":"Liu Z","year":"2023","unstructured":"Liu Z, Liu M, Zhong X, et al.. Global longitudinal strain at 3\u2009months after therapy can predict late cardiotoxicity in breast cancer. Cancer Med. 2023, 12:13374-87. 10.1002\/cam4.6039","journal-title":"Cancer Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45733-x","article-title":"Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms","volume":"15","author":"Yagi R","year":"2024","unstructured":"Yagi R, Goto S, Himeno Y, Katsumata Y, Hashimoto M, MacRae CA, Deo RC. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms. Nat Commun. 2024, 15:2536. 10.1038\/s41467-024-45733-x","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2022.12.015","article-title":"Can global longitudinal strain (GLS) with magnetic resonance prognosticate early cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients, a prospective study?","volume":"97","author":"Kar J","year":"2023","unstructured":"Kar J, Cohen MV, McQuiston SA, Malozzi CM. Can global longitudinal strain (GLS) with magnetic resonance prognosticate early cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients, a prospective study?. Magn Reason Imaging. 2023, 97:68-81. 10.1016\/j.mri.2022.12.015","journal-title":"Magn Reason Imaging"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy","volume":"13","author":"Upshaw JN","year":"2020","unstructured":"Upshaw JN, Finkelman B, Hubbard RA, et al.. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy. JACC Cardiovasc Imaging. 2020, 13:198-210. 10.1016\/j.jcmg.2019.07.018","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad348","article-title":"Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy","volume":"31","author":"Jacobs JE","year":"2024","unstructured":"Jacobs JE, Greason G, Mangold KE, et al.. Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur J Prev Cardiol. 2024, 31:560-6. 10.1093\/eurjpc\/zwad348","journal-title":"Eur J Prev Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/eurjcn\/zvab057","article-title":"Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study","volume":"21","author":"Koop Y","year":"2022","unstructured":"Koop Y, van Zadelhof N, Maas AH, Atsma F, El Messaoudi S, Vermeulen H. Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study. Eur J Cardiovasc Nurs. 2022, 21:235-42. 10.1093\/eurjcn\/zvab057","journal-title":"Eur J Cardiovasc Nurs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2023.07.006","article-title":"Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity","volume":"82","author":"Kinoshita T","year":"2023","unstructured":"Kinoshita T, Onda N, Ohno R, et al.. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity. J Cardiol. 2023, 82:473-80. 10.1016\/j.jjcc.2023.07.006","journal-title":"J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.01.036","article-title":"Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer\u2014from bedside to bench","volume":"311","author":"Chang WT","year":"2020","unstructured":"Chang WT, Feng YH, Kuo YH, et al.. Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer\u2014from bedside to bench. Int J Cardiol. 2020, 311:64-70. 10.1016\/j.ijcard.2020.01.036","journal-title":"Int J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-10023-6","article-title":"Trends in the use of cardiac imaging for women with newly diagnosed breast cancer","volume":"13","author":"Barac A","year":"2020","unstructured":"Barac A, Isaacs C, M Shara N, Lynce F, Desale S, Haynes K, Potosky AL. Trends in the use of cardiac imaging for women with newly diagnosed breast cancer. J Cardiovasc Transl Res. 2020, 13:478-89. 10.1007\/s12265-020-10023-6","journal-title":"J Cardiovasc Transl Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-023-02996-7","article-title":"CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients","volume":"40","author":"Kersten J","year":"2024","unstructured":"Kersten J, Fink V, Kersten M, et al.. CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients. Int J Cardiovasc Imaging. 2024, 40:225-35. 10.1007\/s10554-023-02996-7","journal-title":"Int J Cardiovasc Imaging"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-023-03644-4","article-title":"An in silico platform to predict cardiotoxicity risk of anti-tumor drug combination with hiPSC-CMs based in vitro study","volume":"41","author":"Sang L","year":"2024","unstructured":"Sang L, Zhou Z, Luo S, et al.. An in silico platform to predict cardiotoxicity risk of anti-tumor drug combination with hiPSC-CMs based in vitro study. Pharm Res. 2024, 41:247-62. 10.1007\/s11095-023-03644-4","journal-title":"Pharm Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031084","article-title":"Two-dimensional speckle tracking echocardiography, a powerful method for the evaluation of anthracyclines induced left ventricular insufficiency","volume":"101","author":"Chen W","year":"2022","unstructured":"Chen W, Jiao Z, Li W, Han R. Two-dimensional speckle tracking echocardiography, a powerful method for the evaluation of anthracyclines induced left ventricular insufficiency. Medicine (Baltimore). 2022, 101:e31084. 10.1097\/MD.0000000000031084","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174293","article-title":"Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: safety in real-world data","volume":"15","author":"Toribio-Garc\u00eda I","year":"2023","unstructured":"Toribio-Garc\u00eda I, Olivares-Hern\u00e1ndez A, Miramontes-Gonz\u00e1lez JP, et al.. Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: safety in real-world data. Cancers (Basel). 2023, 15:4293. 10.3390\/cancers15174293","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad210","article-title":"Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights","volume":"30","author":"Shibata T","year":"2023","unstructured":"Shibata T, Nohara S, Morikawa N, et al.. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights. Eur J Prev Cardiol. 2023, 30:1941-9. 10.1093\/eurjpc\/zwad210","journal-title":"Eur J Prev Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2023-323437","article-title":"Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer","volume":"110","author":"Glen C","year":"2024","unstructured":"Glen C, Morrow A, Roditi G, et al.. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer. Heart. 2024, 110:650-6. 10.1136\/heartjnl-2023-323437","journal-title":"Heart"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-023-01575-z","article-title":"Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors","volume":"67","author":"Wei C","year":"2024","unstructured":"Wei C, Fazal M, Loh A, et al.. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors. J Interv Card Electrophysiol. 2024, 67:111-8. 10.1007\/s10840-023-01575-z","journal-title":"J Interv Card Electrophysiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.21037\/qims-23-850","article-title":"Myocardial extracellular volume derived from contrast-enhanced chest computed tomography in longitudinal evaluation of cardiac toxicity in patients treated with immune checkpoint inhibitors","volume":"14","author":"Wang T","year":"2024","unstructured":"Wang T, Ouyang B, Tang L, Li L, Liu Y. Myocardial extracellular volume derived from contrast-enhanced chest computed tomography in longitudinal evaluation of cardiac toxicity in patients treated with immune checkpoint inhibitors. Quant Imaging Med Surg. 2024, 14:3107-20. 10.21037\/qims-23-850","journal-title":"Quant Imaging Med Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00221-5","article-title":"Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics","volume":"10","author":"Abboud K","year":"2024","unstructured":"Abboud K, Umoru G, Trachtenberg B, Ajewole V. Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics. Cardio-oncology. 2024, 10:22. 10.1186\/s40959-024-00221-5","journal-title":"Cardio-oncology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092543","article-title":"Echocardiographic assessment of left ventricular function in three oncologic therapeutic modalities in women with breast cancer: the ONCO-ECHO multicenter study","volume":"13","author":"G\u0105sior T","year":"2024","unstructured":"G\u0105sior T, Zaborska B, Stachowiak P, et al.. Echocardiographic assessment of left ventricular function in three oncologic therapeutic modalities in women with breast cancer: the ONCO-ECHO multicenter study. J Clin Med. 2024, 13:2543. 10.3390\/jcm13092543","journal-title":"J Clin Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12227127","article-title":"Atrial strain assessment for the early detection of cancer therapy-related cardiac dysfunction in breast cancer women (The STRANO STUDY: atrial strain in cardio-oncology)","volume":"12","author":"Di Lisi D","year":"2023","unstructured":"Di Lisi D, Moreo A, Casavecchia G, et al.. Atrial strain assessment for the early detection of cancer therapy-related cardiac dysfunction in breast cancer women (The STRANO STUDY: atrial strain in cardio-oncology). J Clin Med. 2023, 12:7127. 10.3390\/jcm12227127","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2023.101300","article-title":"Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: potential role of endothelial dysfunction","volume":"49","author":"Hammond ST","year":"2023","unstructured":"Hammond ST, Baumfalk DR, Parr SK, et al.. Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: potential role of endothelial dysfunction. Int J Cardiol Heart Vasc. 2023, 49:101300. 10.1016\/j.ijcha.2023.101300","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.933428","article-title":"Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer","volume":"9","author":"Posch F","year":"2022","unstructured":"Posch F, Niedrist T, Glantschnig T, et al.. Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc Med. 2022, 9:933428. 10.3389\/fcvm.2022.933428","journal-title":"Front Cardiovasc Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3892\/or.2022.8468","article-title":"Fluoropyrimidine\u2011induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)","volume":"49","author":"Lombardi P","year":"2023","unstructured":"Lombardi P, Aimar G, Peraldo-Neia C, et al.. Fluoropyrimidine\u2011induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT). Oncol Rep. 2023, 49:31. 10.3892\/or.2022.8468","journal-title":"Oncol Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6869","article-title":"Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity","volume":"9","author":"Buck B","year":"2023","unstructured":"Buck B, Chum AP, Patel M, et al.. Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity. JAMA Oncol. 2023, 9:552-5. 10.1001\/jamaoncol.2022.6869","journal-title":"JAMA Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06695-0","article-title":"Cardiotoxicity among socioeconomically marginalized breast cancer patients","volume":"195","author":"Lu Y","year":"2022","unstructured":"Lu Y, Gehr AW, Anikpo I, et al.. Cardiotoxicity among socioeconomically marginalized breast cancer patients. Breast Cancer Res Treat. 2022, 195:401-11. 10.1007\/s10549-022-06695-0","journal-title":"Breast Cancer Res Treat"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1099545","article-title":"Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer treatment","volume":"14","author":"Valente PM","year":"2023","unstructured":"Valente PM, da Silva PN, da Silva LE, Martins WA, de Castilho SR. Cardiovascular adverse effects associated with the use of anti-HER2 in breast cancer treatment. Front Pharmacol. 2023, 14:1099545. 10.3389\/fphar.2023.1099545","journal-title":"Front Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13824","article-title":"Assessment of tyrosine kinase inhibitors and survival and cardiovascular outcomes of patients with non-small cell lung cancer in Taiwan","volume":"6","author":"Chang WT","year":"2023","unstructured":"Chang WT, Lin HW, Chang TC, Lin SH, Li YH. Assessment of tyrosine kinase inhibitors and survival and cardiovascular outcomes of patients with non-small cell lung cancer in Taiwan. JAMA Netw Open. 2023, 6:e2313824. 10.1001\/jamanetworkopen.2023.13824","journal-title":"JAMA Netw Open"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.11.029","article-title":"Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study","volume":"167","author":"Beukema JC","year":"2022","unstructured":"Beukema JC, de Groot C, Plukker JT, et al.. Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study. Radiother Oncol. 2022, 167:72-7. 10.1016\/j.radonc.2021.11.029","journal-title":"Radiother Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.746114","article-title":"Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I-III breast cancer","volume":"12","author":"Hu W","year":"2021","unstructured":"Hu W, Lv K, Teng R, et al.. Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I-III breast cancer. Front Genet. 2021, 12:746114. 10.3389\/fgene.2021.746114","journal-title":"Front Genet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092320","article-title":"Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin","volume":"14","author":"Lee SH","year":"2022","unstructured":"Lee SH, Cho I, You SC, et al.. Cancer therapy-related cardiac dysfunction in patients treated with a combination of an immune checkpoint inhibitor and doxorubicin. Cancers (Basel). 2022, 14:2320. 10.3390\/cancers14092320","journal-title":"Cancers (Basel)"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000001169","article-title":"Less toxic chemotherapy in locally advanced breast cancer","volume":"113","author":"Carpenter J","year":"2020","unstructured":"Carpenter J, Forero A, Falkson CI, et al.. Less toxic chemotherapy in locally advanced breast cancer. South Med J. 2020, 113:559-63. 10.14423\/SMJ.0000000000001169","journal-title":"South Med J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-316339","article-title":"Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction","volume":"106","author":"Saijo Y","year":"2020","unstructured":"Saijo Y, Kusunose K, Okushi Y, Yamada H, Toba H, Sata M. Relationship between regional left ventricular dysfunction and cancer-therapy-related cardiac dysfunction. Heart. 2020, 106:1752-8. 10.1136\/heartjnl-2019-316339","journal-title":"Heart"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan P","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, et al.. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021, 77:392-401. 10.1016\/j.jacc.2020.11.020","journal-title":"J Am Coll Cardiol"},{"key":"ref45","article-title":"Cancer therapeutics-related cardiac dysfunction among patients with active breast cancer: a cardio-oncology registry","volume":"22","author":"Laufer-Perl M","year":"2020","unstructured":"Laufer-Perl M, Mor L, Milwidsky A, et al.. Cancer therapeutics-related cardiac dysfunction among patients with active breast cancer: a cardio-oncology registry. Isr Med Assoc J. 2020, 22:498-502.","journal-title":"Isr Med Assoc J"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.721080","article-title":"Clinical profile and prognosis of a real-world cohort of patients with moderate or severe cancer therapy-induced cardiac dysfunction","volume":"8","author":"Esteban-Fern\u00e1ndez A","year":"2021","unstructured":"Esteban-Fern\u00e1ndez A, Carvajal Estupi\u00f1an JF, Gavira-G\u00f3mez JJ, et al.. Clinical profile and prognosis of a real-world cohort of patients with moderate or severe cancer therapy-induced cardiac dysfunction. Front Cardiovasc Med. 2021, 8:721080. 10.3389\/fcvm.2021.721080","journal-title":"Front Cardiovasc Med"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01719-5","article-title":"Assessment of coronary artery disease during hospitalization for cancer treatment","volume":"110","author":"Mrotzek SM","year":"2021","unstructured":"Mrotzek SM, Lena A, Hadzibegovic S, et al.. Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol. 2021, 110:200-10. 10.1007\/s00392-020-01719-5","journal-title":"Clin Res Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1873632","article-title":"Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment","volume":"33","author":"Micheletti PL","year":"2021","unstructured":"Micheletti PL, Carla-da-Silva J, Scandolara TB, et al.. Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment. J Chemother. 2021, 33:106-15. 10.1080\/1120009X.2021.1873632","journal-title":"J Chemother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.04.010","article-title":"Cardiology involvement in patients with breast cancer treated with trastuzumab","volume":"2","author":"Demissei BG","year":"2020","unstructured":"Demissei BG, Adusumalli S, Hubbard RA, et al.. Cardiology involvement in patients with breast cancer treated with trastuzumab. JACC CardioOncol. 2020, 2:179-89. 10.1016\/j.jaccao.2020.04.010","journal-title":"JACC CardioOncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.4103\/heartindia.heartindia_18_20","article-title":"Evaluation of left ventricular function using speckle\u2011tracking echocardiography in patients on chemotherapy and\/or thoracic radiotherapy","volume":"8","author":"Singh DK","year":"2020","unstructured":"Singh DK, Jha A, Tiwari BC. Evaluation of left ventricular function using speckle\u2011tracking echocardiography in patients on chemotherapy and\/or thoracic radiotherapy. Heart India. 2020, 8:38-43. 10.4103\/heartindia.heartindia_18_20","journal-title":"Heart India"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert J","year":"2020","unstructured":"Lambert J, Lamacie M, Thampinathan B, et al.. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity. Heart. 2020, 106:817-23. 10.1136\/heartjnl-2019-316297","journal-title":"Heart"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00740","article-title":"Troponins and natriuretic peptides in cardio-oncology patients\u2014data from the ECoR Registry","volume":"11","author":"Hinrichs L","year":"2020","unstructured":"Hinrichs L, Mrotzek SM, Mincu RI, et al.. Troponins and natriuretic peptides in cardio-oncology patients\u2014data from the ECoR Registry. Front Pharmacol. 2020, 11:740. 10.3389\/fphar.2020.00740","journal-title":"Front Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, et al.. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000261","journal-title":"J Immunother Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276993-a-systematic-review-of-the-cardiotoxic-effects-of-targeted-therapies-in-oncology","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T09:13:36Z","timestamp":1722935616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276993-a-systematic-review-of-the-cardiotoxic-effects-of-targeted-therapies-in-oncology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.66258","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}